Back to Treatments

Treatment

Dose-adjusted EPOCH with Rituximab (DA-EPOCH-R)

1
Conditions
3
Trials
3,000
Participants
25%
Average Safety

Condition Evidence

Burkitt lymphoma

3 trials · 3,000 participants

85% effectiveness · 25% safety
Dose-adjusted EPOCH with Rituximab (DA-EPOCH-R) | DFDA